Marinus Pharmaceuticals | MRNS - Capital Ordinário



Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
ALKERMES USD 165.61M 503K 2025-12
Amgen USD 539M 1000K 2025-12
Biogen USD 146.7M 200K 2025-09
Eisai JPY 282.11M 1000 2025-12
Enanta Pharmaceuticals USD 212K 1000 2023-12
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Gilead Sciences USD 1.24B 1000K 2025-12
Incyte USD 199.95M 1.49M 2026-03
Minerva Neurosciences USD 1000 0 2024-09
Neurocrine Biosciences USD 100.1M 400K 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 104.96M 196K 2025-12
Supernus Pharmaceuticals USD 57.12M 1000K 2025-09
UCB EUR 190.36M 365.15K 2025-12
Vertex Pharmaceuticals USD 254M 0 2025-12